BioCryst's Press Release
BioCryst's Press Release
June 6, 2022
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
Takeda's press release
Takeda's press release
April 28, 2022
Héma-Québec Awards Takeda Canada Two-Year Tender for HAE treatment TAKHZYRO®. Click here for the press release in French.
CSL Behring's Press Release
CSL Behring's Press Release
April 6, 2021
CSL Behring announces that HAEGARDA® is now available in all of Canada for the routine prevention of HAE attacks in adolescent and adult patients.
Takeda's Press Release
Takeda's Press Release
November 5, 2020
Takeda Canada announces that negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) are complete and HAE patients in Canada are now one step closer to having access to TAKHZYRO (lanadelumab injection).
click here for details
click here for details
November 22, 2019
TAKHZYRO (lanadelumab) receives positive recommendation fro CADTH’s Canadian Drug Expert Committee (CDEC) for the routine prevention of HAE attacks.
click here for details
click here for details
September 20, 2018
Health Canada has authorized TAKHZYRO (lanadelumab), a first-of-its kind monoclonal antibody treatment for the prevention of HAE attacks.
click here for details
click here for details
August 9, 2017
Berinert approved by Health Canada for the treatment of HAE in paediatric patients.
Archived News
May 15, 2015: New and Convenient Vial Size of CSL Behring’s Berinert® approved by Health Canada for the Treatment of Hereditary Angioedema
July 17, 2014: Firazyr®: First Subcutaneous Treatment for Acute Attacks of Rare and Serious Swelling Disorder Now Available in Canada
October 22, 2012: Health Canada Approves New Drug Submission for Cinryze™ (C1 inhibitor [human])
June 2, 2010: CSL Behring Receives Canadian Notice of Compliance for Berinert®